Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

LQDA - Liquidia Corporation Последние новости | Finranks

Home

/

LQDA

L

Liquidia Corporation (LQDA)

NCM – Цена в реальном времени. Валюта: USD

85.01

-3.04 (-3.45%)

Рынок открыт: Aug 12, 2026, 11:55 AM EDT

88.14

+0.09 (0.10%)

Предыдущая сессия: Aug 11, 2026, 7:56 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Liquidia Q2 Earnings Call Highlights

Liquidia Q2 Earnings Call Highlights

Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.

Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates

Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates

Liquidia Corporation (LQDA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to a loss of $0.49 per share a year ago.

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Liquidia Corporation Reports Second Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an increase in cash and cash equivalents of $61.4 million compared to the first quarter of 2026 Progressing 10 clinical studies supporting YUTREPIA and L606 across known and new indications for inhaled treprostinil MORRISVILLE, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026.

3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET

3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET

Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth drivers amid market volatility.

3 Top Ranked Stocks Breaking Out Now

3 Top Ranked Stocks Breaking Out Now

Lenovo Group, Victoria's Secret and Liquidia Corporation are three stocks from very different industries benefitting from the same catalysts.

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?

LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.

Видео

No Data

There is no data to display

Пресс-релизы

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Liquidia Corporation Reports Second Quarter 2026 Financial Results

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an increase in cash and cash equivalents of $61.4 million compared to the first quarter of 2026 Progressing 10 clinical studies supporting YUTREPIA and L606 across known and new indications for inhaled treprostinil MORRISVILLE, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026.